🟢 Amylyx Pharmaceuticals up 4% today after positive Phase 3 LUCIDITY results and expanded $500M equity offering

Amylyx Pharmaceuticals is trading 4.03% up today at $40.16.

• This follows continued strong investor response to positive Phase 3 LUCIDITY results for avexitide, announced August 18, 2026. The trial met its primary and secondary endpoints, reducing hypoglycemic events by 55% versus placebo.
• Further fueling investor confidence, Amylyx announced on August 20, 2026, an expansion of its common stock offering from $350 million to $500 million, intended to fund pre-commercial activities for avexitide and other corporate purposes.
• Shares previously gained 63.84% on August 18 and 9.94% on August 19.